Bosutinib

Class: Small molecule antibacterial agent

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Active against Enterococcus faecalis, Salmonella typhimurium, and uropathogenic Escherichia coli
Description:	Synthetic compound; approved by FDA as chemotherapeutic drug for treating chronic myelogenous leukaemia; a repurposed drug; does not have an intrinsic antibacterial effect but enhances macrophage clearance of bacterial infection
Institute where first reported:	Singapore-MIT Alliance for Research and Technology Centre, Antimicrobial Drug Resistance Interdisciplinary Research Group, 138602 Singapore
Year first mentioned:	2024
Development status:	Experimental

Chemical structure(s):
Canonical SMILES:	CN1CCN(CCCOC2=CC3=NC=C(C#N)C(=C3C=C2OC)NC4=C(C=C(C(=C4)OC)Cl)Cl)CC1
Isomeric SMILES:	CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
InChI:	InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
InChI Key:	UBPYILGKFZZVDX-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/5328940

External links:
Guide to Pharmacology:	bosutinib
Main Source:	https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00086